Report Detail

Request for Sample of this report

Other Global Cell and Gene Therapy CDMO Market 2023 by Company, Regions, Type and Application, Forecast to 2029

  • RnM4562434
    • |
  • 21 October, 2023
    • |
  • Global
    • |
  • 112 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Other

According to our (Global Info Research) latest study, the global Cell and Gene Therapy CDMO market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
The Global Info Research report includes an overview of the development of the Cell and Gene Therapy CDMO industry chain, the market status of Pharmaceutical Company (Clinical Trial Material CDMOs, Development and Manufacturing CDMOs), Biotechnology Company (Clinical Trial Material CDMOs, Development and Manufacturing CDMOs), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Cell and Gene Therapy CDMO.
Regionally, the report analyzes the Cell and Gene Therapy CDMO markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Cell and Gene Therapy CDMO market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Cell and Gene Therapy CDMO market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Cell and Gene Therapy CDMO industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Clinical Trial Material CDMOs, Development and Manufacturing CDMOs).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Cell and Gene Therapy CDMO market.
Regional Analysis: The report involves examining the Cell and Gene Therapy CDMO market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Cell and Gene Therapy CDMO market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Cell and Gene Therapy CDMO:
Company Analysis: Report covers individual Cell and Gene Therapy CDMO players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Cell and Gene Therapy CDMO This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Pharmaceutical Company, Biotechnology Company).
Technology Analysis: Report covers specific technologies relevant to Cell and Gene Therapy CDMO. It assesses the current state, advancements, and potential future developments in Cell and Gene Therapy CDMO areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Cell and Gene Therapy CDMO market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Cell and Gene Therapy CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Clinical Trial Material CDMOs
Development and Manufacturing CDMOs
Other
Market segment by Application
Pharmaceutical Company
Biotechnology Company
Other
Market segment by players, this report covers
Lonza
Charles River Laboratories
Cytiva
Catalent Biologics
FUJIFILM Diosynth Biotechnologies
BioCentriq
RoslinCT
Thermo Scientific
Mesoblast
Cellularity
Bluebird Bio
Editas Medicine
Andelyn Biosciences
Wuxi Advanced Therapies
AGC Biologics
Pfizer CentreOne
Almac Group
PCI Pharma Services
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Cell and Gene Therapy CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Cell and Gene Therapy CDMO, with revenue, gross margin and global market share of Cell and Gene Therapy CDMO from 2018 to 2023.
Chapter 3, the Cell and Gene Therapy CDMO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Cell and Gene Therapy CDMO market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Cell and Gene Therapy CDMO.
Chapter 13, to describe Cell and Gene Therapy CDMO research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Cell and Gene Therapy CDMO
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Cell and Gene Therapy CDMO by Type
    • 1.3.1 Overview: Global Cell and Gene Therapy CDMO Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Cell and Gene Therapy CDMO Consumption Value Market Share by Type in 2022
    • 1.3.3 Clinical Trial Material CDMOs
    • 1.3.4 Development and Manufacturing CDMOs
    • 1.3.5 Other
  • 1.4 Global Cell and Gene Therapy CDMO Market by Application
    • 1.4.1 Overview: Global Cell and Gene Therapy CDMO Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Pharmaceutical Company
    • 1.4.3 Biotechnology Company
    • 1.4.4 Other
  • 1.5 Global Cell and Gene Therapy CDMO Market Size & Forecast
  • 1.6 Global Cell and Gene Therapy CDMO Market Size and Forecast by Region
    • 1.6.1 Global Cell and Gene Therapy CDMO Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Cell and Gene Therapy CDMO Market Size by Region, (2018-2029)
    • 1.6.3 North America Cell and Gene Therapy CDMO Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Cell and Gene Therapy CDMO Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Cell and Gene Therapy CDMO Market Size and Prospect (2018-2029)
    • 1.6.6 South America Cell and Gene Therapy CDMO Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Cell and Gene Therapy CDMO Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Lonza
    • 2.1.1 Lonza Details
    • 2.1.2 Lonza Major Business
    • 2.1.3 Lonza Cell and Gene Therapy CDMO Product and Solutions
    • 2.1.4 Lonza Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Lonza Recent Developments and Future Plans
  • 2.2 Charles River Laboratories
    • 2.2.1 Charles River Laboratories Details
    • 2.2.2 Charles River Laboratories Major Business
    • 2.2.3 Charles River Laboratories Cell and Gene Therapy CDMO Product and Solutions
    • 2.2.4 Charles River Laboratories Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Charles River Laboratories Recent Developments and Future Plans
  • 2.3 Cytiva
    • 2.3.1 Cytiva Details
    • 2.3.2 Cytiva Major Business
    • 2.3.3 Cytiva Cell and Gene Therapy CDMO Product and Solutions
    • 2.3.4 Cytiva Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Cytiva Recent Developments and Future Plans
  • 2.4 Catalent Biologics
    • 2.4.1 Catalent Biologics Details
    • 2.4.2 Catalent Biologics Major Business
    • 2.4.3 Catalent Biologics Cell and Gene Therapy CDMO Product and Solutions
    • 2.4.4 Catalent Biologics Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Catalent Biologics Recent Developments and Future Plans
  • 2.5 FUJIFILM Diosynth Biotechnologies
    • 2.5.1 FUJIFILM Diosynth Biotechnologies Details
    • 2.5.2 FUJIFILM Diosynth Biotechnologies Major Business
    • 2.5.3 FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Product and Solutions
    • 2.5.4 FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
  • 2.6 BioCentriq
    • 2.6.1 BioCentriq Details
    • 2.6.2 BioCentriq Major Business
    • 2.6.3 BioCentriq Cell and Gene Therapy CDMO Product and Solutions
    • 2.6.4 BioCentriq Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 BioCentriq Recent Developments and Future Plans
  • 2.7 RoslinCT
    • 2.7.1 RoslinCT Details
    • 2.7.2 RoslinCT Major Business
    • 2.7.3 RoslinCT Cell and Gene Therapy CDMO Product and Solutions
    • 2.7.4 RoslinCT Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 RoslinCT Recent Developments and Future Plans
  • 2.8 Thermo Scientific
    • 2.8.1 Thermo Scientific Details
    • 2.8.2 Thermo Scientific Major Business
    • 2.8.3 Thermo Scientific Cell and Gene Therapy CDMO Product and Solutions
    • 2.8.4 Thermo Scientific Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Thermo Scientific Recent Developments and Future Plans
  • 2.9 Mesoblast
    • 2.9.1 Mesoblast Details
    • 2.9.2 Mesoblast Major Business
    • 2.9.3 Mesoblast Cell and Gene Therapy CDMO Product and Solutions
    • 2.9.4 Mesoblast Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Mesoblast Recent Developments and Future Plans
  • 2.10 Cellularity
    • 2.10.1 Cellularity Details
    • 2.10.2 Cellularity Major Business
    • 2.10.3 Cellularity Cell and Gene Therapy CDMO Product and Solutions
    • 2.10.4 Cellularity Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Cellularity Recent Developments and Future Plans
  • 2.11 Bluebird Bio
    • 2.11.1 Bluebird Bio Details
    • 2.11.2 Bluebird Bio Major Business
    • 2.11.3 Bluebird Bio Cell and Gene Therapy CDMO Product and Solutions
    • 2.11.4 Bluebird Bio Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Bluebird Bio Recent Developments and Future Plans
  • 2.12 Editas Medicine
    • 2.12.1 Editas Medicine Details
    • 2.12.2 Editas Medicine Major Business
    • 2.12.3 Editas Medicine Cell and Gene Therapy CDMO Product and Solutions
    • 2.12.4 Editas Medicine Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Editas Medicine Recent Developments and Future Plans
  • 2.13 Andelyn Biosciences
    • 2.13.1 Andelyn Biosciences Details
    • 2.13.2 Andelyn Biosciences Major Business
    • 2.13.3 Andelyn Biosciences Cell and Gene Therapy CDMO Product and Solutions
    • 2.13.4 Andelyn Biosciences Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Andelyn Biosciences Recent Developments and Future Plans
  • 2.14 Wuxi Advanced Therapies
    • 2.14.1 Wuxi Advanced Therapies Details
    • 2.14.2 Wuxi Advanced Therapies Major Business
    • 2.14.3 Wuxi Advanced Therapies Cell and Gene Therapy CDMO Product and Solutions
    • 2.14.4 Wuxi Advanced Therapies Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 Wuxi Advanced Therapies Recent Developments and Future Plans
  • 2.15 AGC Biologics
    • 2.15.1 AGC Biologics Details
    • 2.15.2 AGC Biologics Major Business
    • 2.15.3 AGC Biologics Cell and Gene Therapy CDMO Product and Solutions
    • 2.15.4 AGC Biologics Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.15.5 AGC Biologics Recent Developments and Future Plans
  • 2.16 Pfizer CentreOne
    • 2.16.1 Pfizer CentreOne Details
    • 2.16.2 Pfizer CentreOne Major Business
    • 2.16.3 Pfizer CentreOne Cell and Gene Therapy CDMO Product and Solutions
    • 2.16.4 Pfizer CentreOne Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.16.5 Pfizer CentreOne Recent Developments and Future Plans
  • 2.17 Almac Group
    • 2.17.1 Almac Group Details
    • 2.17.2 Almac Group Major Business
    • 2.17.3 Almac Group Cell and Gene Therapy CDMO Product and Solutions
    • 2.17.4 Almac Group Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.17.5 Almac Group Recent Developments and Future Plans
  • 2.18 PCI Pharma Services
    • 2.18.1 PCI Pharma Services Details
    • 2.18.2 PCI Pharma Services Major Business
    • 2.18.3 PCI Pharma Services Cell and Gene Therapy CDMO Product and Solutions
    • 2.18.4 PCI Pharma Services Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.18.5 PCI Pharma Services Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Cell and Gene Therapy CDMO Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Cell and Gene Therapy CDMO by Company Revenue
    • 3.2.2 Top 3 Cell and Gene Therapy CDMO Players Market Share in 2022
    • 3.2.3 Top 6 Cell and Gene Therapy CDMO Players Market Share in 2022
  • 3.3 Cell and Gene Therapy CDMO Market: Overall Company Footprint Analysis
    • 3.3.1 Cell and Gene Therapy CDMO Market: Region Footprint
    • 3.3.2 Cell and Gene Therapy CDMO Market: Company Product Type Footprint
    • 3.3.3 Cell and Gene Therapy CDMO Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Cell and Gene Therapy CDMO Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Cell and Gene Therapy CDMO Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Cell and Gene Therapy CDMO Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Cell and Gene Therapy CDMO Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Cell and Gene Therapy CDMO Consumption Value by Type (2018-2029)
  • 6.2 North America Cell and Gene Therapy CDMO Consumption Value by Application (2018-2029)
  • 6.3 North America Cell and Gene Therapy CDMO Market Size by Country
    • 6.3.1 North America Cell and Gene Therapy CDMO Consumption Value by Country (2018-2029)
    • 6.3.2 United States Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Cell and Gene Therapy CDMO Consumption Value by Type (2018-2029)
  • 7.2 Europe Cell and Gene Therapy CDMO Consumption Value by Application (2018-2029)
  • 7.3 Europe Cell and Gene Therapy CDMO Market Size by Country
    • 7.3.1 Europe Cell and Gene Therapy CDMO Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 7.3.3 France Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Cell and Gene Therapy CDMO Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Cell and Gene Therapy CDMO Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Cell and Gene Therapy CDMO Market Size by Region
    • 8.3.1 Asia-Pacific Cell and Gene Therapy CDMO Consumption Value by Region (2018-2029)
    • 8.3.2 China Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 8.3.5 India Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Cell and Gene Therapy CDMO Consumption Value by Type (2018-2029)
  • 9.2 South America Cell and Gene Therapy CDMO Consumption Value by Application (2018-2029)
  • 9.3 South America Cell and Gene Therapy CDMO Market Size by Country
    • 9.3.1 South America Cell and Gene Therapy CDMO Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Cell and Gene Therapy CDMO Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Cell and Gene Therapy CDMO Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Cell and Gene Therapy CDMO Market Size by Country
    • 10.3.1 Middle East & Africa Cell and Gene Therapy CDMO Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Cell and Gene Therapy CDMO Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Cell and Gene Therapy CDMO Market Drivers
  • 11.2 Cell and Gene Therapy CDMO Market Restraints
  • 11.3 Cell and Gene Therapy CDMO Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Cell and Gene Therapy CDMO Industry Chain
  • 12.2 Cell and Gene Therapy CDMO Upstream Analysis
  • 12.3 Cell and Gene Therapy CDMO Midstream Analysis
  • 12.4 Cell and Gene Therapy CDMO Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Cell and Gene Therapy CDMO. Industry analysis & Market Report on Cell and Gene Therapy CDMO is a syndicated market report, published as Global Cell and Gene Therapy CDMO Market 2023 by Company, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Cell and Gene Therapy CDMO market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,634.36
    		3,951.54
    		5,268.72
    		3,132.00
    		4,698.00
    		6,264.00
    		494,682.00
    		742,023.00
    		989,364.00
    		291,380.40
    		437,070.60
    		582,760.80
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo